You will be presented with a collection of medical randomized controlled trial (RCT) reports addressing a shared clinical question -- for instance, the efficacy of a medical intervention on a disease or condition. Given the titles and abstracts of these reports, your task is to generate the conclusion of the systematic review article synthesizing the key findings. Your conclusion should be a few sentences long. In your response, include only the conclusion and no other text. The RCT reports are below.



Title 1:
Cetuximab for the treatment of colorectal cancer.
Abstract 1:
BACKGROUND Cetuximab , an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor ( EGFR ) , has activity against colorectal cancers that express EGFR . METHODS From December 2003 to August 2005 , 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine , irinotecan , and oxaliplatin or had contraindications to treatment with these drugs underwent r and omization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care  ( 287 patients ) or best supportive care alone  ( 285 patients ) . The primary end point was overall survival . RESULTS In comparison with best supportive care alone , cetuximab treatment was associated with a significant improvement in overall survival ( hazard ratio for death , 0.77 ; 95 % confidence interval [ CI ] , 0.64 to 0.92 ; P=0.005 ) and in progression-free survival ( hazard ratio for disease progression or death , 0.68 ; 95 % CI , 0.57 to 0.80 ; P<0.001 ) . These benefits were robust after adjustment in a multivariable Cox proportional-hazards model . The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone . Partial responses occurred in 23 patients ( 8.0 % ) in the cetuximab group but in none in the group assigned to supportive care alone ( P<0.001 ) ; the disease was stable in an additional 31.4 % of patients assigned to cetuximab and in 10.9 % of patients assigned to supportive care alone ( P<0.001 ) . Quality of life was better preserved in the cetuximab group , with less deterioration in physical function and global health status scores ( both P<0.05 ) . Cetuximab treatment was associated with a characteristic rash ; a rash of grade 2 or higher was strongly associated with improved survival ( hazard ratio for death , 0.33 ; 95 % CI , 0.22 to 0.50 ; P<0.001 ) . The incidence of any adverse event of grade 3 or higher was 78.5 % in the cetuximab group and 59.1 % in the group assigned to supportive care alone ( P<0.001 ) . CONCLUSIONS Cetuximab improves overall survival and progression-free survival and preserves quality -of-life measures in patients with colorectal cancer in whom other treatments have failed . ( Clinical Trials.gov number , NCT00079066 [ Clinical Trials.gov ] . )


Title 2:
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Abstract 2:
PURPOSE Erlotinib is a highly specific epidermal growth factor receptor ( HER1/EGFR ) tyrosine kinase inhibitor . This phase II study of erlotinib in patients with HER1/EGFR-expressing non-small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response , survival , and symptom improvement . PATIENTS AND METHODS Fifty-seven patients received an oral , continuous daily dose of 150 mg of erlotinib . Assessment s of objective response used WHO and Response Evaluation Criteria in Solid Tumors criteria . The European Organization for Research and Treatment of Cancer Quality of Life Question naire C30 , supplemented with a lung cancer module ,  Quality of Life Question naire LC13 , was used to measure health-related quality of life .  Additional analyses were performed to identify predictors of response and survival . RESULTS The objective response rate was 12.3 % ( 95 % CI , 5.1 % to 23.7 % ) . Responses were observed regardless of type or number of prior chemotherapy regimens . Median survival time was 8.4 months ( 95 % CI , 4.8 to 13.9 months ) , and the 1-year survival rate was 40 % ( 95 % CI , 28 % to 54 % ) . Erlotinib therapy was associated with tumor-related symptom improvement . The drug was well tolerated ; drug-related cutaneous rash and diarrhea were observed in 75 % and 56 % of patients , respectively . One patient experienced toxicity consisting of severe grade 3 rash and diarrhea . Time since diagnosis and good performance status were significant predictors of survival in a multivariate Cox proportional hazards model , whereas HER1/EGFR staining intensity was not . Additionally , survival correlated with the occurrence and severity of rash . CONCLUSION Erlotinib was active and well tolerated in this patient population , and further clinical development is clearly warranted . Cutaneous rash seems to be a surrogate marker of clinical benefit , but this finding should be confirmed in ongoing and future studies
The occurrence of skin rash during treatment with cetuximab and panitumumab represents a significant predictor of the efficacy of these drugs .